Trastuzumab emtansine is a treatment for HER2+ve breast cancer. It consists of 3 parts:
A cytotoxic drug moiety (DM1)
A stable linker
An anti- HER2 trastuzumab monoclonal antibody.1
Metastatic Breast Cancer (MBC)1
UjviraTM (Trastuzumab emtansine) is indicated for the treatment of HER2-positive metastatic breast cancer( if the cancer has spread to other parts of the body) in patients who had previously received trastuzumab and a taxane, separately or in combination.
It can be used for patients who have
- Received prior therapy for locally advanced or metastatic disease, or
- Experienced recurrence during or within six months of completing adjuvant therapy.1
Early Breast Cancer (EBC)1
UjviraTM (Trastuzumab emtansine) is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have received neo-adjuvant taxane-based and HER2- targeted therapy and still have residual invasive cancer tissue in the breast and/or lymph nodes even after treatment.
HER2 protein promotes the growth of cancer cells
Selectivity:UjviraTM is selectively delivered to the tumour cells where HER2 protein is being overexpressed
Inhibitory: UjviraTM(Trastuzumab emtansine) can reduce HER2 signaling by physically binding and inhibiting the HER2 receptors
Cytotoxicity: Furthermore, the drug moeity DM1 gets released inside the cell where it displays its anti-tumor activity which can eventually cause cell death.
UjviraTM is administered as an IV(intravenous) infusion
A dose of 3.6 mg/ kg every 3 weeks (21 days cycle) to be used as IV infusion for all indications
For Early Breast Cancer (EBC) patients, 14 cycles of treatment are given, unless the disease comes back or side effects are unmanageable
For Metastatic Breast Cancer (MBC), treatment is given until there is further spread or in case of unmanageable side effects
HER2: Human epidermal growth factor receptor 2